Genetics and Genomics
Genetics and Genomics
批准号:
10398063
负责人:
John J. Krolewski
金额:
$4.45万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-06-16 至 2024-04-30
关键词:
AddressAfrican American populationApplications GrantsAreaBasic ScienceBig DataBioinformaticsBiological MarkersBiometryCDK4 geneCancer Center Support GrantCancer EtiologyCatchment AreaCell Cycle RegulationCellsClinicalCollaborationsComplementCytokine SignalingDNA MethylationData AnalysesDependenceDevelopmentDirect CostsDiseaseDisease ProgressionDoctor of PhilosophyEndocrineEpigenetic ProcessEtiologyEventFundingFutureGene ExpressionGenesGeneticGenetic TranscriptionGenetsGenitourinary systemGenomeGenome StabilityGenomicsGoalsHormonesJournalsKnowledgeLeadershipMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMalignant neoplasm of ovaryMalignant neoplasm of pancreasMalignant neoplasm of prostateMedicineMethodsModelingMolecularMolecular DiagnosisMolecular and Cellular BiologyNuclear ReceptorsOncogenesOutcomePathologyPathway interactionsPatientsPeer ReviewPharmaceutical PreparationsPharmacologyPhenotypePopulationProductivityPublicationsRecurrent diseaseRefractoryResearchResearch PersonnelResistanceRoleSETDB1 geneScienceSignal PathwaySiteStrategic visionThe SunTherapeuticTherapeutic InterventionTherapeutic TrialsThoracic Surgical ProceduresTranslatingTranslational ResearchTumor BiologyTumor Suppressor GenesTumor Suppressor ProteinsTumor TissueUrologyWorkarmcancer geneticscancer genomicscancer therapychromatin modificationclinical applicationclinical developmentclinical diagnosticscohortdata hubexperiencegene discoverygenome sciencesgenomic locusinnovationinsightinterestinvestigator-initiated trialmalignant breast neoplasmmembermolecular diagnosticsnovelpersonalized approachpersonalized interventionpersonalized medicineprecision medicineprecision oncologyprogramsprogression markerprospectiveprostate cancer progressionrecruitreplication stressresponsetargeted treatmenttherapeutic targettherapy developmenttooltranslational cancer researchtumortumorigenic
中文摘要
遗传学和基因组学(GG)计划的总体目标是发现新的癌症基因,以
阐明不同遗传和表观遗传状态的功能,将机械洞察转化为治疗
目标和相关的生物标记物,并加快向我们的患者提供精确的癌症药物。
这将通过三个目标实现:目标1--询问肿瘤特征的遗传驱动因素;目标2--
将表观遗传状态描述为癌症中的生物标记物和靶点,并目标3-翻译基因和
表观遗传学发现走向临床应用。一些重要的科学发现源于
GG计划说明了总体研究深度、癌症焦点和附加值。此外,GG
该计划开发了独特的肿瘤测序数据和分析方法,以支持精确医学
概念。例如,在GG计划内开发的小组被用于开发
分子诊断公司(OmniSeq),帮助招募罗斯韦尔公园的患者进入
分子篮子试验,如NCI-Match。GG计划研究组合包括研究
解决非洲荷尔蒙难治性乳腺癌和前列腺癌侵袭性的遗传基础-
美国人口-癌症对我们的WNY集水区特别重要。
John Krolewski,医学博士和Erik Knudsen博士是该项目的新联合负责人,他们拥有强大的
对肿瘤遗传学和表观遗传学的基础、临床和人群方面的兴趣。克罗夫斯基医生的
领导层的努力集中在信号/细胞因子通路和泌尿生殖系统恶性肿瘤的基因组学上,
补充了Knudsen博士在细胞周期控制和基因组稳定性领域的重点,并针对
乳腺癌和胃肠癌的通路。该计划由来自9个罗斯威尔的27名成员组成
PARK部门/中心(癌症遗传学和基因组学,个性化医学中心,分子和
细胞生物学、药理学和治疗学、泌尿学、胸外科、生物统计学和生物信息学,
医学和病理学),其同行评审资金总额为310万美元直接成本(NCI资金为190万美元直接成本)
以及总计540万美元的直接成本。自上次续签以来,有12名新成员(9名从外部招募
罗斯韦尔公园)已经加入了该计划。在上一个筹资周期产生的385份出版物中,9%是
方案内出版物和方案间出版物各占44%;50份(13%)出版物是采用影响因子的期刊发表的
>;10.该计划的未来目标是将重点放在做出有影响力的发现的多研究者项目上
并将基础科学转化为临床领域,利用GG科学在基因和
表观遗传水平。
英文摘要
The overall goal of the Genetics and Genomics (GG) Program is to discover novel cancer genes, to
elucidate the function of diverse genetic and epigenetic states, to translate mechanistic insight into therapeutic
targets and associated biomarkers, and to accelerate the delivery of precision cancer medicine to our patients.
This will be accomplished in three aims: Aim 1 – To interrogate genetic drivers of tumor hallmarks; Aim 2 – To
delineate epigenetic states as biomarkers and targets in cancer, and Aim 3 – To translate of genetic and
epigenetic discovery toward clinical application. A number of important scientific discoveries emanated from
the GG Program that illustrate the overall research depth, cancer focus, and added value. Additionally, the GG
Program developed unique tumor sequencing data and analysis approaches to support precision medicine
concepts. For example, panels developed within the GG Program were leveraged toward the development of a
molecular diagnostic company (OmniSeq) that contributes to the recruitment of Roswell Park patients into
molecular basket trials, such as NCI-MATCH. The GG Program research portfolio encompasses studies
addressing genetic basis of aggressiveness of hormone refractory breast and prostate cancer in African-
American populations – cancers that are of particular importance for our WNY catchment area.
John Krolewski, MD, PhD and Erik Knudsen, PhD are new co-Leaders for the Program who have strong
interests in basic, clinical, and population aspects of tumor genetics and epigenetics. Dr. Krolewski's
leadership efforts focus on signaling/cytokine pathways and genomics of genitourinary malignancies, which
complements Dr. Knudsen's focus in the areas of cell cycle control and genomic stability, and targeting such
pathways in breast and gastrointestinal cancers. The Program is comprised of 27 members from nine Roswell
Park departments/centers (Cancer Genetics and Genomics, Center for Personalized Medicine, Molecular and
Cellular Biology, Pharmacology and Therapeutics, Urology, Thoracic Surgery, Biostatistics and Bioinformatics,
Medicine, and Pathology), whose total peer-reviewed funding is $3.1M direct costs (NCI funding $1.9M direct)
and a total funding of $5.4M direct costs. Since the last renewal, 12 new members (nine recruited from outside
Roswell Park) have joined the Program. Of the 385 publications generated over the last funding cycle, 9% are
intra-programmatic and 44% are inter-programmatic; 50 (13%) publications are in journals with an impact factor
>10. Future goals of the Program are focused on multi-investigator projects that make impactful discoveries
and translate basic science into the clinical arena, harnessing GG science to target cancers at the genetic and
epigenetic levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An Androgen-Regulated Cytokine Network Controls Prostate Apoptosis.
-
批准号:9115277
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2011
-
负责人:John J. Krolewski
-
依托单位:
An androgen-regulated cytokine network controls prostate apoptosis
-
批准号:8549718
-
项目类别:
-
资助金额:$4.04万
-
财政年份:2011
-
负责人:John J. Krolewski
-
依托单位:
An androgen-regulated cytokine network controls prostate apoptosis
-
批准号:8187541
-
项目类别:
-
资助金额:$31.75万
-
财政年份:2011
-
负责人:John J. Krolewski
-
依托单位:
An androgen-regulated cytokine network controls prostate apoptosis
-
批准号:8735868
-
项目类别:
-
资助金额:$28.97万
-
财政年份:2011
-
负责人:John J. Krolewski
-
依托单位:
EXPERIMENTAL TISSUE SHARED RESOURCE
-
批准号:7944559
-
项目类别:
-
资助金额:$5.15万
-
财政年份:2009
-
负责人:John J. Krolewski
-
依托单位:
Genetics and Genomics
-
批准号:10641723
-
项目类别:
-
资助金额:$4.23万
-
财政年份:1997
-
负责人:John J. Krolewski
-
依托单位:
EXPERIMENTAL TISSUE SHARED RESOURCE
-
批准号:8740842
-
项目类别:
-
资助金额:$3.74万
-
财政年份:1997
-
负责人:John J. Krolewski
-
依托单位:
TYK2 AND IFNAR1 IN INTERFERON ALPHA SIGNALING
-
批准号:6475792
-
项目类别:
-
资助金额:$25.44万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 TYROSINE KINASE--NORMAL AND PATHOLOGIC FUNCTION
-
批准号:2774052
-
项目类别:
-
资助金额:$15.03万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
Signaling via proteolysis of the interferon receptor
-
批准号:7252514
-
项目类别:
-
资助金额:$25.83万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 TYROSINE KINASE--NORMAL AND PATHOLOGIC FUNCTION
-
批准号:2008070
-
项目类别:
-
资助金额:$22.98万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 AND IFNAR1 IN INTERFERON ALPHA SIGNALING
-
批准号:6044350
-
项目类别:
-
资助金额:$23.98万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 TYROSINE KINASE--NORMAL AND PATHOLOGIC FUNCTION
-
批准号:2837659
-
项目类别:
-
资助金额:$22.81万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 AND IFNAR1 IN INTERFERON ALPHA SIGNALING
-
批准号:6328927
-
项目类别:
-
资助金额:$24.7万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
Signaling via proteolysis of the interferon receptor
-
批准号:7043182
-
项目类别:
-
资助金额:$26.61万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 TYROSINE KINASE--NORMAL AND PATHOLOGIC FUNCTION
-
批准号:2097646
-
项目类别:
-
资助金额:$22.94万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
1TK TYROSINE KINASE--NORMAL AND PATHOLOGIC FUNTION
-
批准号:3201278
-
项目类别:
-
资助金额:$16.92万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 AND IFNAR1 IN INTERFERON ALPHA SIGNALING
-
批准号:6686778
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
1TK TYROSINE KINASE--NORMAL AND PATHOLOGIC FUNTION
-
批准号:3201277
-
项目类别:
-
资助金额:$17.88万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
TYK2 AND IFNAR1 IN INTERFERON ALPHA SIGNALING
-
批准号:6624664
-
项目类别:
-
资助金额:$26.19万
-
财政年份:1992
-
负责人:John J. Krolewski
-
依托单位:
海外基金